Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700011 | 0.94 | EPHX2 (0.62) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL4022912 | 0.94 | EPHX2 (0.62) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL28554753 | 0.93 | EPHX2 (0.80) | EPHX2EPHX1 | |
| SCHEMBL17705940 | 0.93 | EPHX2 (0.75) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL3455859 | 0.92 | EPHX2 (0.83) | EPHX2EPHX1 | |
| SCHEMBL13169536 | 0.92 | EPHX2 (0.83) | EPHX2EPHX1 | |
| SCHEMBL23395780 | 0.90 | EPHX2 (0.85) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL6009189 | 0.89 | EPHX2 (0.61) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL6254027 | 0.89 | EPHX2 (0.61) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL27904589 | 0.88 | SIGMAR1 (0.60) | EPHX2EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | EPHX2 3812/4885EPHX1 2766/4885HDAC2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.